Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more

Opinion & Analysis (NDAQ:SNDX)

    Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia ...

    Streetwise Reports February 3, 2020

    2018 Biotech Watchlist: 'no one space is going to dominate'

    Streetwise Reports January 11, 2018

    2017 Small-Cap Biotech Watchlist update: up 21% at the end of Q2/17

    The Life Sciences Report July 14, 2017

    2017 Small-Cap biotech watchlist update: holding steady in a volatile market

    The Life Sciences Report April 21, 2017

    2017 Small-Cap Biotech Watchlist: takeaways for investors

    The Life Sciences Report January 19, 2017

    19 companies selected for the 2017 Small-Cap Biotech Watchlist

    The Life Sciences Report January 5, 2017